EGFR-targeted inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), are currently being developed and have been approved for use in the treatment of NSCLC, CRC, and SCCHN. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.